Evogene Schedules Fourth Quarter 2024 Financial Results Release
Evogene (Nasdaq: EVGN) (TASE: EVGN), a computational biology company focused on life-science product discovery and development, has announced it will release its fourth quarter 2024 financial results on Thursday, March 6, 2025.
The company will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time) on the same day. Interested parties can register for the Zoom conference call through the provided link. The conference recording will be made available on the company's website following the event.
Evogene (Nasdaq: EVGN) (TASE: EVGN), un'azienda di biologia computazionale focalizzata sulla scoperta e sviluppo di prodotti nel campo delle scienze della vita, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre 2024 il giovedì 6 marzo 2025.
L'azienda ospiterà una conferenza telefonica per discutere i risultati alle 9:00 AM ora orientale (4:00 PM ora di Israele) dello stesso giorno. Le parti interessate possono registrarsi per la conferenza Zoom tramite il link fornito. La registrazione della conferenza sarà disponibile sul sito web dell'azienda dopo l'evento.
Evogene (Nasdaq: EVGN) (TASE: EVGN), una empresa de biología computacional centrada en el descubrimiento y desarrollo de productos en ciencias de la vida, ha anunciado que publicará sus resultados financieros del cuarto trimestre de 2024 el jueves 6 de marzo de 2025.
La empresa llevará a cabo una llamada de conferencia para discutir los resultados a las 9:00 AM hora del Este (4:00 PM hora de Israel) el mismo día. Las partes interesadas pueden registrarse para la llamada de conferencia de Zoom a través del enlace proporcionado. La grabación de la conferencia estará disponible en el sitio web de la empresa después del evento.
Evogene (Nasdaq: EVGN) (TASE: EVGN)은 생명 과학 제품 발견 및 개발에 중점을 둔 컴퓨터 생물학 회사로, 2024년 4분기 재무 결과를 2025년 3월 6일 목요일에 발표할 것이라고 발표했습니다.
회사는 같은 날 동부 표준시 기준 오전 9시 (이스라엘 시간 오후 4시)에 결과를 논의하기 위한 컨퍼런스 콜을 개최할 예정입니다. 관심 있는 분들은 제공된 링크를 통해 Zoom 컨퍼런스 콜에 등록할 수 있습니다. 컨퍼런스 녹음은 이벤트 후 회사 웹사이트에서 제공될 예정입니다.
Evogene (Nasdaq: EVGN) (TASE: EVGN), une entreprise de biologie computationnelle axée sur la découverte et le développement de produits dans le domaine des sciences de la vie, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre 2024 le jeudi 6 mars 2025.
L'entreprise organisera un appel conférence pour discuter des résultats à 9h00, heure de l'Est (16h00, heure d'Israël) le même jour. Les parties intéressées peuvent s'inscrire à l'appel conférence Zoom via le lien fourni. L'enregistrement de la conférence sera disponible sur le site web de l'entreprise après l'événement.
Evogene (Nasdaq: EVGN) (TASE: EVGN), ein Unternehmen für computergestützte Biologie, das sich auf die Entdeckung und Entwicklung von Produkten im Bereich der Lebenswissenschaften konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal 2024 am Donnerstag, den 6. März 2025, veröffentlichen wird.
Das Unternehmen wird am selben Tag um 9:00 Uhr Eastern Time (16:00 Uhr israelischer Zeit) eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Interessierte Parteien können sich über den bereitgestellten Link für die Zoom-Konferenz registrieren. Die Aufzeichnung der Konferenz wird nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Zoom conference call scheduled for March 6, 2025, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To join the conference, please register in advance:
https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:
- Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
- Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
- AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
- Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.
For more information, please visit: www.evogene.com.
Contact
ir@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1947468/4576969/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-fourth-quarter-2024-financial-results-release-302381283.html
SOURCE Evogene
FAQ
When will Evogene (EVGN) release its Q4 2024 earnings?
What time is Evogene's (EVGN) Q4 2024 earnings call?
How can investors join Evogene's (EVGN) Q4 2024 earnings call?
Will Evogene's (EVGN) Q4 2024 earnings call be available for replay?
